89zr-pembrolizumab
mAbexperimentalImaging agent
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2016 (NCT02760225)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 89-Zirconium
Oral
No
Parenteral
No
Topical
No
Also known as
- 89zr-pembrolizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03065764 | Phase 2 | Jan 20, 2017 | Free University of Amsterdam, Merck, University of Amsterdam |
| NCT02760225 | N/A | Sep 1, 2016 | University of Groningen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
| University of Amsterdam | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Groningen | Academic/Hospital | 1 | 1 | 1 | 2016 |
4 organizations
Page 1 / 1